According to a study involving nerve cells, the combination of CBD and CBG might be efficient to reduce brain and nerve cell inflammation.
In fact , Neural inflammation occurs along with various neurological disorders, including Amyotrophic Lateral Sclerosis (ALS). Although the use of cannabinoids for reducing pain is increasingly popular among humans. It is still under-studies.
Carried out at the IRCCS Centro Neurolesi “Bonino Pulejo” in Italy. This study on the subject is available by clicking on this link. Therefore, scientists sought to study the anti-inflammatory, antioxidant and anti-apoptotic properties of 2 non-psychoactive phytocannabinoids, cannabigerol (CBG) and cannabidiol (CBD).
Materials and methods: The motor neuron cell line NSC-34 differentiated by serum deprivation in addition to treatment of all-trans retinoic acid (RA) is a valid model for studying the molecular events related to neurodegeneration in ALS.
Pretreatment with CBG (at doses of 2.5 and 5 µM) alone and in combination with CBD (at doses of 2.5 and 5 µM) was able to reduce the neuroinflammation induced by LPS-stimulated macrophage culture medium. In particular, pre-treatment with CBD at a dose of 5 µM decreased levels of TNF-α and increased the expression of IL10 and IL-37.
The combination of CBG-CBD at a dose of 5 µM also reduced the activation of nuclear factor NF-kB with little degradation of the kappa B alpha inhibitor (IkBα). CBG and CBD co-administered at a dose of 5 µM decreased iNOS expression and increased Nrf2 levels.
Besides, pre-treatment with the combination of two non-psychoactive cannabinoids, Bax protein expression was down-regulated and Bcl-2 expression was up-regulated.
Our data show anti-inflammatory, antioxidant and anti-apoptotic effects mediated by PPARγ. Our results provide preliminary support on the potential therapeutic application of a CBG-CBD combination for further preclinical studies.